cannabidiol + cannabigerol + tetrahydrocannabinol

This is a combination of three phytocannabinoids derived from the Cannabis sativa plant: - **Cannabidiol (CBD):** A non-psychoactive cannabinoid with anticonvulsant, anti-inflammatory, anxiolytic, and neuroprotective properties. It acts primarily as a negative allosteric modulator of the cannabinoid CB1 receptor and has additional activity at serotonin 5-HT1A receptors. - **Cannabigerol (CBG):** A non-psychoactive cannabinoid considered the precursor to other cannabinoids. CBG exhibits agonist activity at alpha-2 adrenergic receptors, partial agonism at both CB1 and CB2 receptors, and interacts with several other targets including PPARγ and various TRP channels. It shows potential for anti-inflammatory, analgesic, hypotensive, neuroprotective, and metabolic effects[5][6]. - **Tetrahydrocannabinol (THC):** The primary psychoactive component of cannabis. THC is a weak partial agonist at both CB1 and CB2 receptors; its activation leads to psychoactive effects as well as appetite stimulation, analgesia, muscle relaxation/spasticity reduction[3]. The combination may provide synergistic or additive therapeutic benefits for conditions such as chronic pain management, spasticity in multiple sclerosis (as seen with similar combinations like nabiximols), inflammation-related disorders, epilepsy (primarily via CBD), anxiety disorders (CBD), neurodegenerative diseases (CBG/CBD/THC), metabolic syndrome/hypertension (CBG), among others[2][9]. The exact clinical profile depends on the ratio of each component.

Other names

CBD + CBG + THCCAMTREA formulationCBD + CBG + THC 133/66/4mg